A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), represents an unprecedented global public health emergency with economic and social consequences. One of the main concerns in the development of vaccines is the antibody-dependen...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of immunopathology and pharmacology 2021, Vol.35, p.20587384211050199
Hauptverfasser:	Sánchez-Zuno, Gabriela Athziri, Matuz-Flores, Mónica Guadalupe, González-Estevez, Guillermo, Nicoletti, Ferdinando, Turrubiates-Hernández, Francisco Javier, Mangano, Katia, Muñoz-Valle, José Francisco
Format:	Artikel
Sprache:	eng
Schlagworte:	Adaptive Immunity Antibodies, Viral - immunology Antibody-Dependent Enhancement Coronaviruses COVID-19 COVID-19 - immunology COVID-19 - prevention & control COVID-19 - virology COVID-19 vaccines COVID-19 Vaccines - therapeutic use Host-Pathogen Interactions Humans Immune response Immunity, Innate Letter to the Editor Pandemics Public health SARS-CoV-2 - immunology SARS-CoV-2 - pathogenicity Severe acute respiratory syndrome coronavirus 2 Vaccination Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), represents an unprecedented global public health emergency with economic and social consequences. One of the main concerns in the development of vaccines is the antibody-dependent enhancement phenomenon, better known as ADE. In this review, we provide an overview of SARS-CoV-2 infection as well as the immune response generated by the host. On the bases of this principle, we also describe what is known about the ADE phenomenon in various viral infections and its possible role as a limiting factor in the development of new vaccines and therapeutic strategies.
ISSN:	2058-7384 0394-6320 2058-7384
DOI:	10.1177/20587384211050199